Skip to main content
. 2019 Dec 5;111(1):229–238. doi: 10.1111/cas.14238

Figure 3.

Figure 3

Five‐year event‐free survival (EFS) and overall survival (OS) of relapsed acute lymphoblastic leukemia (ALL) with TP53 alterations in 69 patients with paired samples. A, 5‐year EFS for relapsed ALL patients with TP53 wild‐type (WT) and TP53 alterations. B, 5‐year OS for relapsed ALL patients with TP53 WT and TP53 alterations